Citigroup
TCRX icon

Citigroup’s TScan Therapeutics TCRX Stock Holding History

Citigroup’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 5872
2025
Q4 		– Sell
-1,088
Closed -$1.98K – 6468
2025
Q3 		$1.98K Sell
1,088
-10,684
-91% -$18.9K ﹤0.01% 5486
2025
Q2 		$17.1K Sell
11,772
-16,374
-58% -$23.7K ﹤0.01% 5113
2025
Q1 		$38.8K Sell
28,146
-12,097
-30% -$26.2K ﹤0.01% 4946
2024
Q4 		$122K Buy
40,243
+12,450
+45% +$56.4K ﹤0.01% 4733
2024
Q3 		$138K Buy
27,793
+19,347
+229% +$117K ﹤0.01% 4603
2024
Q2 		$49.4K Sell
8,446
-108,475
-93% -$854K ﹤0.01% 4584
2024
Q1 		$928K Buy
116,921
+43,758
+60% +$275K ﹤0.01% 3090
2023
Q4 		$427K Buy
+73,163
New +$335K ﹤0.01% 3520

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citigroup's TCRX Position: Q1 2026 in Review

Citigroup opened a new position in TScan Therapeutics (TCRX) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5872 among its holdings. This is a return to the name: Citigroup previously reported a position in TCRX as recently as Q3 2025.

Citigroup first reported a position in TCRX in Q4 2023 and has held it in 9 quarters since. The position peaked at $928K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Citigroup held 1 share of TScan Therapeutics worth $1 as of Q1 2026.
  • TScan Therapeutics was a new Citigroup position in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5872 holding.
  • Citigroup first reported a position in TScan Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Citigroup's TScan Therapeutics position peaked at $928K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.